Skip to main content
Premium Trial:

Request an Annual Quote

Pacific Biosciences to Raise $175M in Public Stock Offering

NEW YORK – Pacific Biosciences said on Wednesday that it is selling 17.5 million shares of its common stock at a price of $10 per share in an underwritten public offering for expected net proceeds of $175 million.

The firm said in a statement that it intends to use the proceeds for R&D, commercial expansion, and working capital and general corporate purposes.

Goldman Sachs, Morgan Stanley, Cowen, and Allen & Company are acting as joint bookrunning managers for the offering.

PacBio will grant the underwriters a 30-day option to purchase up to an additional 2.6 million shares of its common stock at the offering price, less underwriting discounts and commissions.

The offering is expected to close on or around Jan. 27, subject to customary closing conditions.

Menlo Park, California-based PacBio sold approximately 11.2 million shares in a private investment in public equity (PIPE) financing in 2021 to fund its acquisition of Omniome.

It also raised approximately $170 million between two stock offerings in 2020.

In Wednesday morning trading on the Nasdaq, shares of PacBio were flat at $10.84.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.